Lilly Adds PhIII Intranasal Glucagon To Diabetes Arsenal
This article was originally published in Scrip
Eli Lilly & Co has acquired the worldwide rights to Locemia Solutions' Phase III intranasal glucagon product for the treatment of severe hypoglycemia – which it hopes will be the first needle-free option to gain approval for this indication.
You may also be interested in...
The latest drug development news and highlights from our US FDA Performance Tracker.
Zealand Pharma stresses fast onset of dasiglucagon, which it plans to file on its own but develop commercially through partnership.
For In Vivo's 13th annual Deals of the Year contest, we selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A. The polls are closed, and it is time to reveal the winners.